Last reviewed · How we verify
NCT06128460
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.
Phase 2 trial testing Zimberelimab in Cervical Cancer in 24 participants. Not yet recruiting.
1 December 2025
Quick facts
| Lead sponsor | Obstetrics & Gynecology Hospital of Fudan University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 1 December 2023 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2029 |
Drugs / interventions tested
- Zimberelimab — full drug profile →
- Platinum (PLATINUM) — full drug profile →
- radiotherapy — full drug profile →
Conditions studied
- Cervical Cancer — all drugs for Cervical Cancer →
Sponsor
Obstetrics & Gynecology Hospital of Fudan University
Who can join
Adults 18 to 70, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Locally advanced cervical cancer (stage IB3, IIA2) patients with postoperative risk factors need better treatment. We initiated a clinical study to explore the effectiveness of adjuvant chemoradiotherapy followed by Zimberelimab for these patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06128460
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Zimberelimab
Trials testing the same drug.
- NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
- NCT07283848 — Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma · Phase 2 · withdrawn
- NCT06431633 — Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously · Phase 3 · recruiting
- NCT06759649 — A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies · Phase 1 · recruiting
- NCT06155396 — A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard T · Phase 2 · recruiting
Other recruiting trials for Cervical Cancer
Currently open trials in the same condition.
- NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
- NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Other Obstetrics & Gynecology Hospital of Fudan University trials
Trials by the same sponsor.
- NCT07523308 — Efficacy and Safety of Intra-operative Dual Laparoscopy and Neo-rectoscopy vs Conventional Laparoscopy for Bowel Endomet · NA · not yet recruiting
- NCT07318701 — Multi-agent LLMs for Decision Support in Cervical Cancer During Pregnancy · NA · not yet recruiting
- NCT07130240 — Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 a · Phase 2 · recruiting
- NCT07202728 — A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01) · recruiting
- NCT06904131 — A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06128460 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Obstetrics & Gynecology Hospital of Fudan University
- Last refreshed: 30 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06128460.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing